Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial - Griesinger, Frank; Curigliano, G.; Thomas, Michael; Subbiah, V.; Baik, C. S.; Tan, D. S. W.; Lee, D. H.; Misch, D.; Garralda, E.; Kim, D. -W.; van der Wekken, A. J.; Gainor, J. F.; et al. (Annals of oncology, 2022)
Gesehen am 19.01.2023